semaglutide essence trial for MASH in #ESSENCE #Semaglutide hits both primary endpoints in NASH trial 📍62.9% resolved steatohepatitis (vs 34.3% placebo) 📍36.8% showed fibrosis improvement (vs 22.4% placebo) 📍Combined response: 32.7% vs 16.1% semaglutide essence Original Article: Phase

First, an amino acid substitution at position 8 (alanine replaced with aminoisobutyric acid) provides resistance to DPP-4 degradation, the primary enzyme responsible for native GLP-1 breakdown

Not everyone on Semaglutide suffers from Ozempic face, but there are other concerns

Future investigations should include diabetic populations with PD to properly assess the efficacy profile of GLP-1 receptor agonists and determine whether the observed improvement in the MDS-UPDRS Part III score (MD = 2.88

We have very few people

Generally not associated with chronic liver damage, though foci of cellular alteration may occur in damaged liver

A.HabenerJ